These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19425054)

  • 1. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
    Cappello P; Tomaino B; Chiarle R; Ceruti P; Novarino A; Castagnoli C; Migliorini P; Perconti G; Giallongo A; Milella M; Monsurrò V; Barbi S; Scarpa A; Nisticò P; Giovarelli M; Novelli F
    Int J Cancer; 2009 Aug; 125(3):639-48. PubMed ID: 19425054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation.
    Capello M; Caorsi C; Bogantes Hernandez PJ; Dametto E; Bertinetto FE; Magistroni P; Rendine S; Amoroso A; Novelli F
    Immunol Lett; 2015 Sep; 167(1):11-6. PubMed ID: 26096821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody signature in human ductal pancreatic adenocarcinoma.
    Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
    J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells.
    Zhou W; Capello M; Fredolini C; Piemonti L; Liotta LA; Novelli F; Petricoin EF
    J Proteome Res; 2010 Jun; 9(6):2929-36. PubMed ID: 20433201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
    Principe M; Ceruti P; Shih NY; Chattaragada MS; Rolla S; Conti L; Bestagno M; Zentilin L; Yang SH; Migliorini P; Cappello P; Burrone O; Novelli F
    Oncotarget; 2015 May; 6(13):11098-113. PubMed ID: 25860938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
    Tomaino B; Cappello P; Capello M; Fredolini C; Sperduti I; Migliorini P; Salacone P; Novarino A; Giacobino A; Ciuffreda L; Alessio M; Nisticò P; Scarpa A; Pederzoli P; Zhou W; Petricoin Iii EF; Liotta LA; Giovarelli M; Milella M; Novelli F
    J Proteome Res; 2011 Jan; 10(1):105-12. PubMed ID: 20455595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.
    Schmitz-Winnenthal FH; Volk C; Z'graggen K; Galindo L; Nummer D; Ziouta Y; Bucur M; Weitz J; Schirrmacher V; Büchler MW; Beckhove P
    Cancer Res; 2005 Nov; 65(21):10079-87. PubMed ID: 16267034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
    Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F
    Gastroenterology; 2013 May; 144(5):1098-106. PubMed ID: 23333712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
    Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
    Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma.
    Niccolai E; Cappello P; Taddei A; Ricci F; D'Elios MM; Benagiano M; Bechi P; Bencini L; Ringressi MN; Coratti A; Cianchi F; Bonello L; Di Celle PF; Prisco D; Novelli F; Amedei A
    Int J Oncol; 2016 Jul; 49(1):393-401. PubMed ID: 27210467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
    Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
    Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of c-kit expression in pancreatic adenocarcinoma: a novel stem cell marker responsible for the progression of the disease.
    Amsterdam A; Raanan C; Polin N; Melzer E; Givol D; Schreiber L
    Acta Histochem; 2014 Jan; 116(1):197-203. PubMed ID: 23978330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters.
    Wu W; Zhang J; Zhou L; You L; Zhao Y; Li J
    Sci China Life Sci; 2012 Sep; 55(9):747-52. PubMed ID: 23015122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducing a humoral immune response to pancreatic cancer antigen.
    Seifert M; Seifert G; Wolff-Vorbeck G; Langenmair E; Hopt UT; Wittel UA
    Cell Immunol; 2016 Dec; 310():150-155. PubMed ID: 27663207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pentamer guided HLA-restricted epitope identification for mucoprotein 4 antigen of pancreatic ductal adenocarcinoma].
    Gao WT; Zhang JJ; Zhu Y; Wei JS; Meng K; Chen JM; Wu JL; Miao Y
    Zhonghua Wai Ke Za Zhi; 2010 Sep; 48(18):1416-24. PubMed ID: 21092580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
    Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.